Track record · closed signal

Eli Lilly and Company (LLY) — closed signal from April 6, 2026

Target reached Published before the outcome was known, scored automatically when the window closed on July 5, 2026 — +30.9% at the close.

Predicted vs. what happened

LLY price · publication thesis → realized outcomesplit-adjusted

$915.00 – $940.00Entry zone — fair-value band

$927.55Published — price the day we called it

$1,075.96Target — the price the thesis aimed for

$1,238.00Peak — highest point inside the window, not a realized return

$1,213.91Window close — end-of-window price, context only

What happened

Target reached

Reached its target in 50 days.

At window close

+30.9%

realized, from the publication price to the last close inside the window

Peak gain

+33.5%

peak, from the publication price — not a realized return

S&P 500, same window

+13.3%

SPY over the identical days, dividend-adjusted

Window close

$1,213.91

last close inside the window, ended July 5, 2026

Peak price

$1,238.00

peak on June 29, 2026 — not a realized return

Days to target

The thesis — published April 6, 2026

Predicted growth

+16%

over the measurement window

Target price

$1,075.96

the price the thesis aimed for

Entry zone

$915.00 – $940.00

the fair-value band we waited for

Price at publication

$927.55

published April 6, 2026

Confidence

85%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Eli Lilly combines steady profit momentum with defensive traits. A recent approval for an oral obesity drug and a sleep-focused partnership create several near-term ways the stock can gain attention. The price sits near a supportive trend area rather than being overstretched, so the setup allows upside even if markets get choppy and healthcare narrows leadership.

Primary drivers

Oral obesity drug approval opens a large growth platform
Sleep partnership widens development pipeline and short-term catalysts
Consistent earnings results back a premium healthcare stance
Defensive demand can keep the stock steadier in volatile markets

How it played out

LLY: target reached in 50 days

Lyra published LLY at $927.55 with an expected gain of 16% and a $1,075.96 target. The thesis pointed to an oral obesity drug approval, a sleep partnership, consistent earnings and defensive demand during volatile markets.

The shares reached the target in 50 days. They later peaked at $1,238 on June 29, a gain of 33.5% within the window. LLY ended the window at $1,213.91, still above the target. The thesis played out and exceeded its stated price objective.

What happened during the window

On April 30, Eli Lilly reported first-quarter revenue growth of 56% and raised its full-year guidance. On June 7, the company announced additional results from studies of its oral obesity drug in women across stages of menopause.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All LLY signals